ANI Pharmaceuticals reports positive Phase 4 uveitis implant data

2 min read Updated on 13 Jul 2026, 05:04 PM

Reviewed by

Naman SScanX News Team

AI Summary

ANI Pharmaceuticals reported positive topline results from its Phase 4 SYNCHRONICITY trial for the Fluocinolone Acetonide Intravitreal Implant, meeting co-primary endpoints for visual acuity and central subfield thickness improvements at 6 months. The trial showed a mean BCVA gain of +3.6 letters and a CST reduction of -157.5 microns in 108 patients. Adverse events were consistent with prior studies, with detailed results slated for presentation in 4Q 2026.

*this image is generated using AI for illustrative purposes only.

ANI Pharmaceuticals, Inc. announced positive topline data from its Phase 4, open-label, single-arm SYNCHRONICITY clinical trial of Fluocinolone Acetonide Intravitreal Implant in patients with chronic non-infectious uveitis affecting the posterior segment of the eye. The trial met both co-primary endpoints assessing mean change from baseline in best corrected visual acuity (BCVA) letter score and mean change from baseline in central subfield thickness (CST) at 6 months with statistical significance.

SYNCHRONICITY Trial Results

The intent-to-treat (ITT) population included 108 patients. Patients in the ITT population had a mean change in baseline BCVA of +3.6 letters gained (p= <0.0077) at 6 months, with a mean BCVA letter score of 62.5 at baseline compared to 65.8 at month 6. Patients in the ITT population had a mean change in baseline CST of -157.5 microns (p= <.0001) at 6 months, with a mean CST of 505.7 microns at baseline compared to 348.8 microns at month 6.

Metric	Baseline	Month 6	Mean Change	P-Value
BCVA Letter Score	62.5	65.8	+3.6	<0.0077
Central Subfield Thickness (microns)	505.7	348.8	-157.5	<.0001

Safety Profile

The most common adverse events seen in SYNCHRONICITY were consistent with prior trials of the fluocinolone acetonide intravitreal implant. In the safety population, 29% of patients (n=31/108) experienced treatment-related treatment-emergent adverse events; the most common were ocular hypertension in 6% of patients (n=7) and cataract in 5% of patients (n=5). Separately, 18% of patients (n=19/108) experienced an IOP increase of ≥25 mmHg, and 7% of patients (n=8/108) required any laser or surgical IOP-lowering intervention.

Study Design and Population

SYNCHRONICITY was a prospective, Phase 4, open-label, single-arm, two year follow-up study conducted in the U.S. to evaluate the inflammatory control associated with fluocinolone acetonide intravitreal implant, 0.18 mg. Patients enrolled in the study had to have a diagnosis of active, recurrent, unilateral or bilateral NIU-PS with a duration of at least 3 months from initial diagnosis. The study population had a mean age of 64 years and the majority of participants were female (65%). At baseline, 69% of study participants had a history of ocular surgery prior to enrollment.

Future Presentations

Detailed results and additional analyses will be presented at medical conferences in 4Q 2026. The implant is designed to release the corticosteroid fluocinolone acetonide in the eye for up to 36 months.

How will the 36-month sustained release of the implant impact long-term patient adherence compared to current treatments?

What regulatory hurdles remain for ANI Pharmaceuticals following these positive Phase 4 results?

How will the safety profile, particularly the risk of ocular hypertension, influence physician adoption?

Analyst Rating and Target

The rating reiteration comes as the firm assesses the current valuation and future prospects of ANI Pharmaceuticals. The $124 price target provides a specific benchmark for investors regarding the stock's anticipated trajectory.